Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and
Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity …

Solid organ transplantation (SOT) is a life-saving procedure and an established treatment for
patients with end-stage organ failure. However, transplantation is also accompanied by …

摘要背景: 本研究旨在探讨肝移植后新发糖尿病(new‐onset diabetes after transplantatio,
NODAT) 的发病率及相关危险因素, 以及NODAT 对并发症和患者长期生存的影响. 方法 …

Rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1), extends
the life spans of yeast, flies, and mice. Calorie restriction, which increases life span and …

The protein kinase mechanistic target of rapamycin (mTOR) functions as a central regulator
of metabolism, integrating diverse nutritional and hormonal cues to control anabolic …

Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ
transplantation. PTDM has been associated with greater mortality and increased infections …

TOR (target of rapamycin) and its mammalian ortholog mTOR have been discovered in an
effort to understand the mechanisms of action of the immunosuppressant drug rapamycin …

From the dawn of civilization, humanity has dreamed of immortality. So why didn't the
discovery of the anti-aging properties of mTOR inhibitors change the world forever? I will …

A consensus meeting was held in Vienna on September 8–9, 2013, to discuss diagnostic
and therapeutic challenges surrounding development of diabetes mellitus after …

New therapeutic approaches to counter the increasing prevalence of obesity and type 2
diabetes mellitus are in high demand. Deregulation of the phosphoinositide-3-kinase …